These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 17268528)

  • 21. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
    Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
    Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.
    Schwaller J; Frantsve J; Aster J; Williams IR; Tomasson MH; Ross TS; Peeters P; Van Rompaey L; Van Etten RA; Ilaria R; Marynen P; Gilliland DG
    EMBO J; 1998 Sep; 17(18):5321-33. PubMed ID: 9736611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transgenic mice expressing either bovine growth hormone (bGH) or human GH releasing hormone (hGRH) have increased splenic progenitor cell colony formation and DNA synthesis in vitro and in vivo.
    Blazar BR; Brennan CA; Broxmeyer HE; Shultz LD; Vallera DA
    Exp Hematol; 1995 Dec; 23(13):1397-406. PubMed ID: 7498369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.
    Chung A; Hou Y; Ohgami RS; Von Gehr A; Fisk DG; Roskin KM; Li X; Gojenola L; Bangs CD; Arber DA; Fire AZ; Cherry AM; Zehnder JL; Gotlib J; Merker JD
    Cancer Genet; 2017 Oct; 216-217():10-15. PubMed ID: 29025582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.
    MacKenzie KL; Dolnikov A; Millington M; Shounan Y; Symonds G
    Blood; 1999 Mar; 93(6):2043-56. PubMed ID: 10068678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.
    Taylor SJ; Dagger SA; Thien CB; Wikstrom ME; Langdon WY
    Blood; 2012 Nov; 120(19):4049-57. PubMed ID: 22990016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment.
    Mooney CJ; Cunningham A; Tsapogas P; Toellner KM; Brown G
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28498310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of protein kinase C-{epsilon} in the mouse epidermis leads to a spontaneous myeloproliferative-like disease.
    Wheeler DL; Reddig PJ; Ness KJ; Leith CP; Oberley TD; Verma AK
    Am J Pathol; 2005 Jan; 166(1):117-26. PubMed ID: 15632005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in mice.
    Graham MT; Abram CL; Hu Y; Lowell CA
    PLoS One; 2013; 8(10):e77542. PubMed ID: 24116232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia.
    Kurihara Y; Mizuno H; Honda A; Shimura A; Fujioka Y; Maki H; Kurokawa M
    J Cell Mol Med; 2022 Feb; 26(3):950-952. PubMed ID: 35019216
    [No Abstract]   [Full Text] [Related]  

  • 32. A
    Venable ER; Gagnon MF; Pitel BA; Palmer JM; Peterson JF; Baughn LB; Hoppman NL; Greipp PT; Ketterling RP; Patnaik MS; Kelemen K; Xu X
    Cold Spring Harb Mol Case Stud; 2023 Feb; 9(1):. PubMed ID: 36627146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ZBTB44-FLT3 fusion in a patient with a myeloproliferative neoplasm.
    Zhou X; Yang C; Zou Z; Lang X; Chen P; Chen S; Wang K; Chen Y; Hao Y; Chen N; Ding J; Li Y; Shen Y; Xiao S
    Br J Haematol; 2020 Oct; 191(2):297-301. PubMed ID: 32866288
    [No Abstract]   [Full Text] [Related]  

  • 34. Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657.
    Cain JA; Grisolano JL; Laird AD; Tomasson MH
    Blood; 2004 Jul; 104(2):561-4. PubMed ID: 15044254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of caspase pathways limits CD4
    Holloway AJ; Saito TB; Naqvi KF; Huante MB; Fan X; Lisinicchia JG; Gelman BB; Endsley JJ; Endsley MA
    Retrovirology; 2024 May; 21(1):8. PubMed ID: 38693565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
    Gutierrez-Camino A; Richer C; Ouimet M; Fuchs C; Langlois S; Khater F; Caron M; Beaulieu P; St-Onge P; Bataille AR; Sinnett D
    Br J Cancer; 2024 Feb; 130(2):317-326. PubMed ID: 38049555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?
    Troadec E; Dobbelstein S; Bertrand P; Faumont N; Trimoreau F; Touati M; Chauzeix J; Petit B; Bordessoule D; Feuillard J; Bastard C; Gachard N
    Leukemia; 2017 Feb; 31(2):514-517. PubMed ID: 27795560
    [No Abstract]   [Full Text] [Related]  

  • 38. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1.
    Kim M; Kim J; Kim JR; Han E; Park J; Lim J; Kim Y; Han K; Kim HJ; Min WS; Cho B
    Mol Biol Rep; 2015 Feb; 42(2):451-6. PubMed ID: 25287662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
    Li L; Piloto O; Nguyen HB; Greenberg K; Takamiya K; Racke F; Huso D; Small D
    Blood; 2008 Apr; 111(7):3849-58. PubMed ID: 18245664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.
    Lee BH; Tothova Z; Levine RL; Anderson K; Buza-Vidas N; Cullen DE; McDowell EP; Adelsperger J; Fröhling S; Huntly BJ; Beran M; Jacobsen SE; Gilliland DG
    Cancer Cell; 2007 Oct; 12(4):367-80. PubMed ID: 17936561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.